This filing contains no new clinical data or financial updates — it is a routine publication announcement. Monitor for initiation of the larger, adequately powered Phase 2b/3 study for the next-generation delayed-release formulation, which would represent a material catalyst.
Price Chart
Executive Summary
Immuron announced the publication of its Phase 2 clinical trial data for once-daily oral Travelan in the journal Scientific Reports. The study demonstrated a statistically significant 50% reduction in ETEC challenge-related adverse events versus placebo (P=0.0001), but did not meet its primary efficacy endpoints due to a lower-than-anticipated placebo attack rate (33% vs 70%). The data is not new — it was previously disclosed to the ASX on March 7, 2024 — and the filing represents a routine update with no change in the company's financial or regulatory outlook.
Key Facts
- Phase 2 data for once-daily Travelan published in Scientific Reports (Nature journal).
- Study did not meet primary efficacy endpoints due to lower-than-expected placebo attack rate (33% vs 70%).
- Statistically significant 50% reduction in ETEC challenge-related adverse events vs placebo (P=0.0001).
- Data previously announced to ASX on March 7, 2024 — not new information.
- Company is developing a next-generation delayed-release capsule formulation for once-daily dosing.
- No financial figures, revenue, or earnings data provided in this filing.
Financial Impact
No financial impact disclosed; publication of previously known clinical data.
Risk Factors
- Primary endpoint not met in Phase 2 study; regulatory path for Travelan remains uncertain.
- Company requires substantial additional funding for larger trials (as noted in forward-looking statements).
- Travelan is currently sold only as a dietary supplement in the U.S., limiting revenue potential.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-108742 |
| Document: ea0308406-6k_immuron.htm | 0001213900-26-108742 |
| Document: 0001213900-26-108742-index-headers.html | 0001213900-26-108742 |
| Document: 0001213900-26-108742-index.html | 0001213900-26-108742 |
| Document: 0001213900-26-108742.txt | 0001213900-26-108742 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9200 (−1.08%) |
Oct 23, 2026 3d ago | 6-K | $0.9320 | awaiting T+60 | — | $0.9200 (−1.29%) |
Oct 23, 2026 3d ago | 424B5 | $0.9320 | awaiting T+60 | — | $0.9200 (−1.29%) |
Oct 21, 2026 5d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9200 (−3.06%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9200 (−6.32%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9200 (−11.54%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9200 (−22.69%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9200 (−22.69%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9200 (−26.69%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9200 (−48.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers